Skip to main content
. 2021 Feb 12;24(3):102173. doi: 10.1016/j.isci.2021.102173

Figure 1.

Figure 1

A somatic synonymous BAP1 mutation leads to its loss of function and worsens patient prognosis

(A) Kaplan-Meier curves for the indicated groups from the KIRC-TCGA data set. The green arrow indicates the index patient. The blue arrow depicts the worsening of the median overall survival from tumors with PBRM1 mutations to tumors with mutations in both BAP1 and PBRM1 (B/P).

(B) Genomic DNA sequence of the KIRC-TCGA patient displaying the somatic synonymous c.936T>G, p.G312G mutation in exon 11 of BAP1 in the tumor (T) but not in the normal (N) kidney.

(C) Log2-transformed RNA-Seq Expectation-Maximization (RSEM) normalized gene expression for BAP1 from KIRC-TCGA.

(D) Reverse phase protein array (RPPA) analysis for BAP1 from KIRC-TCGA stratifying for patients with BAP1 and PBRM1 mutations individually or for both genes (B/P). Index patient was compared with each group by the one-sample t test.

(E and F) Ribosomal protein S6 phosphorylation at S235/S236 (E) and at S240/S244 (F). For all plots, the green dot or dashed line indicates the index patient.